XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Consideration Payable
 9 Months Ended
Sep. 30, 2024
Consideration Payable [Abstract]  
Consideration payable
11.Consideration payable

 

On January 15, 2024, the Company entered into a license agreement with a Biotechnology company to use their proprietary technology and process to assist in formulating stem cells. The remaining amount of the payments to be made in accordance with the interest-free payment schedule disclosed in Note 8 is $950,000.

 

The Company has accounted for a discount, using a market interest rate of 11.75%, on the consideration payable to reflect the imputed interest on future installments, totaling $138,548.

 

   Consideration
payable		 
Outstanding, December 31, 2023  $
-
 
Additions   861,452 
Payment   (50,000)
Accretion expense   58,259 
Outstanding, September 30, 2024  $869,711 
      
Consideration payable – current   350,000 
Consideration payable – non-current  $519,711